# Subjective Experience Following Psilocybin

> **NCT06768944** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Calgary** · enrollment: 128 (estimated)

## Conditions studied

- Investigating the Importance of the Subjective Psychedelic Experience

## Interventions

- **DRUG:** Psilocybin high-dose
- **DRUG:** Psilocybin low-dose
- **DRUG:** Risperidone 1 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06768944
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-01
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768944, "Subjective Experience Following Psilocybin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06768944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*